机器人对比传统微创食管切除术治疗食管癌的Meta分析
该系统评价与Meta分析纳入18项研究、共2932例食管癌患者,比较机器人辅助微创食管切除术(RAMIE)与传统微创食管切除术(MIE)的围术期结局与长期生存。RAMIE组在总淋巴结、腹部淋巴结及左喉返神经旁淋巴结清扫数量上显著更多,肺炎发生率更低,3年无病生存率更高;两组3年总生存率相似,其他围术期结局无显著差异。
要点
- RAMIE较MIE清扫总淋巴结、腹部淋巴结及左喉返神经旁淋巴结更多。
- RAMIE组肺炎发生率低于MIE组(9.61% vs 14.74%)。
- RAMIE组3年无病生存率高于MIE组(77.98% vs 70.65%)。
核心结论
- RAMIE是治疗可切除食管癌安全可行的MIE替代方案,围术期结局相当,在腹腔淋巴结、左喉返神经旁淋巴结清扫及3年无病生存方面可能更优,尤其对食管鳞癌。
研究设计与样本
- 该系统评价与Meta分析已在PROSPERO注册(CRD42021260963),系统检索数据库后纳入18项研究共2932例患者,其中RAMIE组1418例、MIE组1514例,92.88%为鳞状细胞癌、29.83%接受新辅助治疗、38.93%为III-IV期。
主要发现
- RAMIE组总淋巴结数[23.35(95%CI: 21.41-25.29)vs 21.98(95%CI: 20.31-23.65);MD=1.18;95%CI: 0.06-2.30;P=0.04]、腹部淋巴结数[9.05(95%CI: 8.16-9.94)vs 7.75(95%CI: 6.62-8.88);MD=1.04;95%CI: 0.19-1.89;P=0.02]及左喉返神经旁淋巴结数[1.74(95%CI: 1.04-2.43)vs 1.34(95%CI: 0.32-2.35);MD=0.22;95%CI: 0.09-0.35;P<0.001]均显著高于MIE组。
- RAMIE组肺炎发生率显著低于MIE组[9.61%(95%CI: 7.38%-11.84%)vs 14.74%(95%CI: 11.62%-18.15%);OR=0.73;95%CI: 0.58-0.93;P=0.01]。
- 手术时间、失血量、住院时间、30/90天死亡率及R0切除率在两组间无显著差异;3年总生存率相似,RAMIE组3年无病生存率更高[77.98%(95%CI: 72.77%-82.43%)vs 70.65%(95%CI: 63.87%-77.00%);OR=1.42;95%CI: 1.11-1.83;P=0.006]。
关键数值与推荐
- RAMIE组总淋巴结数均值23.35(95%CI: 21.41-25.29),MIE组21.98(95%CI: 20.31-23.65),MD=1.18(95%CI: 0.06-2.30;P=0.04)。
- RAMIE组腹部淋巴结数均值9.05(95%CI: 8.16-9.94),MIE组7.75(95%CI: 6.62-8.88),MD=1.04(95%CI: 0.19-1.89;P=0.02)。
- RAMIE组左喉返神经旁淋巴结数均值1.74(95%CI: 1.04-2.43),MIE组1.34(95%CI: 0.32-2.35),MD=0.22(95%CI: 0.09-0.35;P<0.001)。
- RAMIE组肺炎发生率9.61%(95%CI: 7.38%-11.84%),MIE组14.74%(95%CI: 11.62%-18.15%),OR=0.73(95%CI: 0.58-0.93;P=0.01)。
- RAMIE组3年无病生存率77.98%(95%CI: 72.77%-82.43%),MIE组70.65%(95%CI: 63.87%-77.00%),OR=1.42(95%CI: 1.11-1.83;P=0.006)。
临床怎么用
- 在可切除食管癌(尤其鳞癌)中,RAMIE可作为MIE的替代方案,围术期安全性相当且肺炎风险更低。
- 若治疗目标侧重腹腔及左喉返神经旁淋巴结清扫或3年无病生存,RAMIE可能更具优势。
- 现有证据仍待随机对照研究进一步验证RAMIE的长期获益。
局限性
- 纳入研究以观察性研究为主,需进一步随机研究评估RAMIE相比MIE的长期获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To give a comprehensive review of the literature comparing perioperative outcomes and long-term survival with robotic-assisted minimally invasive esophagectomy (RAMIE) versus minimally invasive esophagectomy (MIE) for esophageal cancer. BACKGROUND: Curative minimally invasive surgical treatment for esophageal cancer includes RAMIE and conventional MIE. It remains controversial whether RAMIE is comparable to MIE. METHODS: This review was registered at the International Prospective Register of Systematic Reviews (CRD42021260963). A systematic search of databases was conducted. Perioperative outcomes and long-term survival were analyzed and subgroup analysis was conducted. Cumulative meta-analysis was performed to track therapeutic effectiveness. RESULTS: Eighteen studies were included and a total of 2932 patients (92.88% squamous cell carcinoma, 29.83% neoadjuvant therapy, and 38.93% stage III-IV), 1418 underwent RAMIE and 1514 underwent MIE, were analyzed. The number of total lymph nodes (LNs) [23.35 (95% CI: 21.41-25.29) vs 21.98 (95% CI: 20.31-23.65); mean difference (MD) = 1.18; 95% CI: 0.06-2.30; P =0.04], abdominal LNs [9.05 (95% CI: 8.16-9.94) vs 7.75 (95% CI: 6.62-8.88); MD = 1.04; 95% CI: 0.19-1.89; P =0.02] and LNs along the left recurrent laryngeal nerve [1.74 (95% CI: 1.04-2.43) vs 1.34 (95% CI: 0.32-2.35); MD = 0.22; 95% CI: 0.09-0.35; P <0.001] were significantly higher in the RAMIE group. RAMIE is associated with a lower incidence of pneumonia [9.61% (95% CI: 7.38%-11.84%) vs 14.74% (95% CI: 11.62%-18.15%); odds ratio = 0.73; 95% CI: 0.58-0.93; P =0.01]. Meanwhile, other perioperative outcomes, such as operative time, blood loss, length of hospital stay, 30/90-day mortality, and R0 resection, showed no significant difference between the two groups. Regarding long-term survival, the 3-year overall survival was similar in the two groups, whereas patients undergoing RAMIE had a higher rate of 3-year disease-free survival compared with the MIE group [77.98% (95% CI: 72.77%-82.43%) vs 70.65% (95% CI: 63.87%-77.00%); odds ratio = 1.42; 95% CI: 1.11-1.83; P =0.006]. A cumulative meta-analysis conducted for each outcome demonstrated relatively stable effects in the two groups. Analyses of each subgroup showed similar overall outcomes. CONCLUSIONS: RAMIE is a safe and feasible alternative to MIE in the treatment of resectable esophageal cancer with comparable perioperative outcomes and seems to indicate a possible superiority in LNs dissection in the abdominal cavity, and LNs dissected along the left recurrent laryngeal nerve and 3-year disease-free survival in particular in esophageal squamous cell carcinoma. Further randomized studies are needed to better evaluate the long-term benefits of RAMIE compared with MIE.
引用
- Zhang Y, Dong D, Cao Y, et al. Robotic Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer: A Meta-analysis. Ann Surg. 2022. PMID: 36538615. doi:10.1097/SLA.0000000000005782
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。